High-dose cytosine arabinoside and L-asparaginase therapy for poor-risk adult acute nonlymphocytic leukemia. A retrospective study
| Autor: | Craig S. Rosenfeld, Alan Winkelstein, Richard K. Shadduck, Carol Evans, Zella R. Zeigler |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Cancer Research
medicine.medical_specialty Asparaginase Chemotherapy Performance status business.industry medicine.medical_treatment Retrospective cohort study medicine.disease Gastroenterology Surgery chemistry.chemical_compound Regimen Leukemia Oncology Refractory chemistry hemic and lymphatic diseases Internal medicine medicine Cytarabine business medicine.drug |
| Zdroj: | Cancer. 65:2624-2630 |
| ISSN: | 1097-0142 0008-543X |
| Popis: | The effectiveness and toxicities of high-dose cytosine arabinoside with L-asparaginase (HiDAC-ASNase) were evaluated in 41 patients with "poor risk" acute nonlymphocytic leukemia (ANLL). Twenty-four patients had either refractory or relapsed primary ANLL, and 17 had ANLL secondary to prior cytotoxic chemotherapy or an underlying hematologic disorder. The overall complete remission (CR) rate was 37%. The CR rates for primary and secondary ANLL were almost identical. Furthermore, advanced age alone did not adversely influence the CR rate. The median CR duration was 302 days with no differences between primary and secondary ANLL. The induction death rate was 24%. Predictors for induction deaths included poor initial performance status, fever at the time of presentation, low cholesterol and/or albumin, and an initial bone marrow aspirate with greater than 50% blasts. These data indicate that HiDAC-ASNase is a moderately effective regimen for patients with poor prognosis ANLL including secondary ANLL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text